This article first appeared on GuruFocus .
Release Date: November 17, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Shilpa Medicare Ltd ( BOM:530549 ) recorded the highest quarterly EBITDA in the company's history, showcasing strong financial performance.
-
The company is experiencing growth in its API business, particularly in oncology and non-oncology segments, with new product filings in the US and Europe.
-
Shilpa Medicare Ltd is expanding its capacity for key products like tranexamic acid, with plans to commission additional capacity in the next financial year.
-
The formulation business division successfully launched its first NCE program in India, indicating progress in innovative product development.
-
The company reported a strong EBITDA margin of 30% for both the quarter and the first half, reflecting improved operational efficiency and profitability.
Negative Points
-
The company faces challenges with US FDA inspections, with no current updates on the status of their Jujla plant.
-
There is uncertainty regarding the commercialization timeline for some products, such as the OLC contract, which may impact future revenue projections.
-
The competitive landscape in the European oncology injectable market is intense, requiring a focus on complex generics and differentiated products to maintain market share.
-
Licensing income is variable and can be lopsided depending on the stage of product development, leading to potential fluctuations in revenue.
-
The company is late in entering the semaglutide market, which may affect its ability to capture significant market share despite its backward integration strategy.
Q & A Highlights
-
Warning! GuruFocus has detected 5 Warning Signs with BOM:530549.
-
Is BOM:530549 fairly valued? Test your thesis with our free DCF calculator.
Q: As the pharma industry shifts towards more specialty drugs and global partnerships, how is Shilpa Medicare planning to position itself for long-term growth beyond quarterly numbers? A: Mr. Kesha Kurtada, Executive Director and CEO, explained that Shilpa Medicare has historically invested in complex and specialty divisions such as biologics and transdermal facilities. The company plans to monetize these investments over the next 3 to 5 years, leveraging its technical know-how and complex pipeline to maintain a strategic edge.
Q: With rising costs in raw materials, compliance, and R&D, how does Shilpa Medicare plan to maintain steady margins without slowing growth? A: Mr. Atesh Dalal, CFO, stated that the company employs an agile system to monitor market changes and offset challenges. They focus on predicting market situations, stocking up on materials when necessary, and leveraging operational efficiencies. The company also explores cost-reduction strategies and sustainable solutions to maintain profitability.
Q: Regarding the launch of NorUDCA in India, what is the market potential and competitive landscape for this product? A: Mr. Kesha Kurtada highlighted that NorUDCA is a differentiated product targeting NAFLD patients, with a significant patient base in India. The company expects to capture 10-20% of the treated NAFLD population over the next 3 to 5 years. The revenue will primarily come from supply prices rather than licensing income.
Q: Has Shilpa Medicare faced any challenges due to US tariffs on its 505B2 portfolio, and how is it managing existing products in the US market? A: Mr. Kesha Kurtada clarified that all critical 505B2 launches for the US market are conducted through US FDA-approved third-party CMOs, ensuring no direct impact from tariffs on their operations.
Q: What is the status of the US FDA inspection at the Jujla plant, and are there any updates? A: Mr. Atesh Dalal mentioned that the company will provide updates on the US FDA inspections as they become available. Currently, there are no new updates to share.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
